Conatus Pharmaceuticals Inc (CNAT) 6.66 $CNAT Conatus

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 1:14 PM

Conatus Pharmaceuticals Inc (CNAT) 6.66 $CNAT

Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH
GlobeNewswire - Thu Apr 23, 6:00AM CDT
Late-Breaker Posters on Results From Emricasan Phase 2 NAFLD/NASH and ACLF Clinical Trials
CNAT: 6.66 (-0.15)

Nasdaq stocks posting largest percentage increases
AP - Thu Apr 16, 12:29PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
HTBX: 6.89 (-0.71), NFLX: 558.40 (-0.66), SAGE: 58.57 (-1.37), ARCW: 7.12 (-0.13), TZOO: 12.89 (-0.14), GLMD: 9.14 (-0.72), LAYN: 5.79 (+0.27), CNAT: 6.66 (-0.15), ANGI: 6.16 (-0.24), VLTC: 11.54 (+0.50), MNTA: 20.13 (+0.04), AREX: 7.98 (-0.36)

Fatty Liver Disease Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Thu Apr 16, 10:30AM CDT
The report "Fatty Liver Disease - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Fatty Liver Disease. Fatty liver disease is characterized by increased accumulation of fat, especially triglycerides, in the liver cells. Many people with fatty liver disease experience no symptoms, especially in the early stage of the disease. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/fatty-liver-...eport.html .
RPTP: 10.81 (+0.10), GILD: 103.69 (-1.52), CNAT: 6.66 (-0.15), CCXI: 7.62 (-0.27), DRRX: 2.11 (-0.46), TBRA: (), NVS: 104.28 (-1.22)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 4:36PM CDT

FIS: 64.11 (-0.40), BAK: 8.39 (+0.12), STV: 4.25 (-0.09), CNAT: 6.66 (-0.15), KTEC: 13.27 (+0.28), KOS: 8.69 (+0.02), TOWR: 26.95 (-0.27), GCA: 7.66 (-0.31), EXTR: 2.55 (-0.02), XOMA: 3.60 (-0.02)

Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Wed Apr 08, 3:01PM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today the completion of its previously announced underwritten public offering of 4,025,000 shares of its common stock, including 525,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares. All shares in the offering were sold by Conatus at a price to the public of $5.75 per share. Net proceeds to Conatus from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $21.4 million.
CNAT: 6.66 (-0.15)

UPDATE -- Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting
GlobeNewswire - Wed Apr 08, 8:14AM CDT
In a release issued earlier this morning by Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), two subheadings were missing from the text. The subheadings have been added and the updated release follows in its entirety.
CNAT: 6.66 (-0.15)

Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting
GlobeNewswire - Wed Apr 08, 6:01AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) announced today that three posters addressing clinical results with emricasan, the company's first-in-class, orally active pan-caspase protease inhibitor, have been accepted for presentation at The International Liver Congress(TM) 2015, the 50 Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 22-26, 2015.
CNAT: 6.66 (-0.15)

Regulus Soars As AstraZeneca Grabs NASH Drug Rights
at Investor's Business Daily - Tue Apr 07, 6:41PM CDT
Regulus Therapeutics (RGLS) stock leapt Tuesday night as AstraZeneca (AZN) took its NASH fatty liver disease candidate for testing as part of their microRNA alliance. They join a crowded field of drugmakers developing treatments and making...
GILD: 103.69 (-1.52), CNAT: 6.66 (-0.15), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ICPT: 283.20 (-2.22), ABBV: 66.07 (+1.82), RGLS: 17.49 (-0.80)

Conatus to Present at Needham Healthcare Conference
GlobeNewswire - Tue Apr 07, 6:10AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) announced today its scheduled presentation of the company's programs and outlook at the 14 Annual Needham Healthcare Conference on Wednesday, April 15, 2015, at 2:20 p.m. ET, in New York. A copy of the presentation will be available in the Investor Center of the company's website at www.conatuspharma.com.
CNAT: 6.66 (-0.15)

Conatus prices public offering at USD5.75 per share
M2 - Fri Apr 03, 6:18AM CDT
Biotechnology company Conatus Pharmaceuticals (NasdaqGM:CNAT) disclosed on Thursday that it has priced its public offering of 3,500,000 shares of its common stock at a price of USD5.75 per share.
CNAT: 6.66 (-0.15)

Conatus Pharmaceuticals (CNAT) Stock Falls Today After Pricing Public Offering
at The Street - Thu Apr 02, 1:07PM CDT
Shares of Conatus Pharmaceuticals (CNAT) were down in afternoon trading Thursday after the company priced an underwritten public offering of its common stock.
CNAT: 6.66 (-0.15)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 11:45AM CDT

KRNT: 14.90 (+0.08), ARCW: 7.12 (-0.13), TOF: 4.80 (+0.59), SSN: 1.58 (-0.01), CNAT: 6.66 (-0.15), NYMX: 1.39 (-0.05), SEAC: 6.88 (-0.20), UACL: 22.75 (+0.45), WBAI: 17.20 (+0.16), LBIX: 3.37 (-0.10), CARB: 11.05 (-0.14), EBIO: 11.19 (+0.69), CTSO: 7.52 (+0.50), AKER: 4.65 (unch), SQBG: 13.22 (-0.11), TRIB: 17.18 (+0.02), OCRX: 3.89 (+0.08), TCPI: 3.86 (-0.07), TRUE: 15.62 (-0.09), FHCO: 3.05 (-0.06)

Conatus prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 10:20AM CDT

CNAT: 6.66 (-0.15)

The Zacks Analyst Blog Highlights: Horizon Pharma, Hyperion Therapeutics, Conatus, Amgen and Biogen - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Horizon Pharma, Hyperion Therapeutics, Conatus, Amgen and Biogen
BIIB: 401.71 (-28.57), CNAT: 6.66 (-0.15), HZNP: 31.75 (+0.97), AMGN: 167.91 (-1.26), HPTX: 45.97 (-0.11)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 8:13AM CDT

KMX: 69.97 (-0.75), CARB: 11.05 (-0.14), TXMD: 7.12 (-0.12), CERU: 6.27 (+0.07), CNAT: 6.66 (-0.15), RPRX: 8.43 (-0.06), LBIO: 12.34 (-0.08), FXCM: 2.08 (-0.03), CAPN: 6.87 (+0.01), WBAI: 17.20 (+0.16)

Conatus Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Thu Apr 02, 8:00AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today that it has priced an underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $5.75 per share. Gross proceeds, before underwriting discounts and commissions and estimated offering costs, are expected to be approximately $20.1 million.
CNAT: 6.66 (-0.15)

Conatus initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 3:14PM CDT

CNAT: 6.66 (-0.15)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pet Care Spending Defies Economic Pressures, Survey Shows

Consumer Loyalty to Pet Health Spending Stands Tall When it rains, it pours, but try telling that to pet owners. According to Elanco Animal Health's latest data dump, 93% of surveyed pet owners in the U.S. are guarding their pet health spending like a hawk. Yep, they either maintained or upped their spending in the past three months—and they ain't planning to back down...

Pen Needles Market to Hit $3.37B by 2031: Growth Ahead

Big Numbers in the Needle Game When you're staring down the numbers popping out of this pen needles market projection, it's hard to ignore—shooting from a respectable $2.16 billion in 2026 to a hefty $3.37 billion by 2031. We're talking a 9.3% CAGR that'll have investors pulling out their calculators or maybe rubbing their hands in downright glee, depending on their...

TELUS Boosts Board with Strategic Executive Appointments

New Faces on the TELUS Board: Shaping the Future Alright, investors, here's the scoop straight from the trenches: TELUS (TSX:TU) is shaking things up at the top. Marc Allera and Bill Thomas are stepping into the fray as the newest members of the board, effective January 1, 2027. If you're not familiar with these names, it's time to tune in because they've got the chops to...

Tetragon Declares Dividend Amidst Regulation Challenges

What Keeps Investors on Their Toes Tetragon Financial Group is ringing the dividend bell again—a solid 12 cents a share coming your way. But don't just kick your feet up and watch the cash roll in; there's a tangle of juicy tidbits and regulatory strings attached that make this more than your run-of-the-mill payout announcement. A Look at the Dividend Breakdown For...

Used Truck Inventory Shrinks as Auction Values Rise

October's Tailspin in Used Truck Inventory If you've been around the block in the trucking industry, the latest from Sandhills Global might just knock your socks off. Their October rundown is out, and it's looking bleak for anyone trying to grab a used truck or trailer at a bargain. We're seeing a real crunch in inventory, and that’s an understatement. Navigating a...

Hanon Systems Reports 2026 Q3 Results: Profit Soars

Profit Surges Despite Revenue Dip When a company's profit jumps up while sales take a slight nosedive, they're doing something right—or maybe they've got a lucky rabbit's foot. Hanon Systems just rolled out their numbers for Q3 2026, and here's what's cooking: operating profit soared a whopping 26.6% year-on-year to hit KRW 120.6 billion, even while revenue stumbled a...

Pepsi Drivers in Georgia Gear Up for a Strike Showdown

Teamsters Turn Up the Heat in Georgia Well, folks, buckle up because we've got ourselves a brewing labor storm down in Georgia! Over 100 Pepsi-Cola drivers, holding the steering wheel firm under Teamsters Local 528, are about ready to slam their fists down and go on strike. They've had it up to here with management's tap-dancing around negotiations. Drivers Say Enough Is...

Reliving the Legacy of Friendship at Friends & Co

Reconnecting With History In an era dominated by fleeting digital interactions, the heartening effort by Friends & Co stands out. This nonprofit is digging back into its roots and asking folks to share tales of the deep bonds formed over the past fifty years under its former guise, Little Brothers – Friends of the Elderly Twin Cities. The mission? To celebrate...

ASUR's October Traffic Sees Mixed Results Across Regions

A Patchwork of Gains and Losses Take a look at Grupo Aeroportuario del Sureste, S.A.B. de C.V. (NYSE: ASR), and you’ll see a mixed bag when it comes to October 2026’s passenger traffic. While some regions like Puerto Rico and Colombia took a step forward, others like Mexico and Costa Rica tripped up, resulting in an overall decline of 0.9% compared to last October....

Lands' End Brings Holiday Magic to Chicago

Something about the first chill in the air can spark that holiday vibe, and Lands' End sure knows how to bottle it. They’ve concocted a hefty dose of festive magic in Chicago with their weekend shindig, a mix of holiday nostalgia, community cheer, and retail bravado. Now, I'm not here to just wax poetic about winter hats and fuzzy pajamas, but this event's got a twinkle...